Drug Approval | 21 March 2022
Zydus receives PAS approval for Mycophenolate Mofetil
The drug is indicated for use in combination with other drugs
The drug is indicated for use in combination with other drugs
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Nebivolol is used alone or together with other medicines to treat high blood pressure
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
It is only the second generic application approved by the USFDA
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia
Tislelizumab is now approved for seven indications in China
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
The product will be manufactured at Lupin’s facility in Goa, India
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
